The 7 references in paper Е. Панченко П. (2014) “БЕЗОПАСНОСТЬ АНТИКОАГУЛЯНТНОЙ ТЕРАПИИ У БОЛЬНЫХ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ. КАК ОБЕСПЕЧИТЬ ПАЦИЕНТУ ОПТИМАЛЬНОЕ ЛЕЧЕНИЕ?” / spz:neicon:aterotromboz:y:2014:i:2:p:11-18

1
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. Focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace, 2012, 14: 1385–413.
(check this in PDF content)
2
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2013, 15: 625–651.
(check this in PDF content)
3
Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Российскийкардиологический журнал, 2014, 4 (3).
(check this in PDF content)
4
Connolly et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med., 2009, 361(12): 1139-1151.
(check this in PDF content)
5
Patel et al. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med., 2011, 365(10): 883–891.
(check this in PDF content)
6
Granger et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation N Engl J Med. 2011;365(10): 981-992.
(check this in PDF content)
7
Connolly S et al. Apixaban in Patients with Atrial Fibrillation. N Engl J Med., 2011, 364: 806–817.
(check this in PDF content)